HCR 563 Module 4 Assignment 2: Building Quality Into Clinical Trials Example

Plan, Do, Check, Act: Building Quality Into a Clinical Trial Before It Starts

Student Name

MS in Regulatory Science, Arizona State University

HCR 563: Fundamentals of Regulatory Affairs

Instructor Name

Month Day, Year

Plan, Do, Check, Act: Building Quality Into a Clinical Trial Before It Starts

Introduction

Quality in a clinical trial means that participants are protected and the results can be trusted. For years, trials pursued quality mainly by inspecting data after the fact, checking every field against every source document. That approach is expensive and still misses the errors that matter most. A better approach, now built into good clinical practice, is to design quality into the trial from the start and improve it continuously (U.S. Food and Drug Administration, 2025). The Plan, Do, Check, Act cycle, first popularized in manufacturing and echoed in the quality systems the course text describes for FDA-regulated products (Pacifici & Bain, 2018), gives that idea a structure. This essay applies it to a composite trial of a new drug for heart failure at 60 sites.

Plan: Say What You Do

Planning is where most quality is won or lost. A multistakeholder project on quality by design concluded that trial teams should identify, before the protocol is final, the factors most critical to participant safety and the reliability of results, and focus effort there (Meeker-O'Connell et al., 2016). For the heart failure trial, the team identifies five: correct diagnosis of heart failure with reduced ejection fraction at enrollment, accurate adjudication of the primary endpoint of heart failure hospitalization or cardiovascular death, monitoring of potassium and kidney function, adherence to study drug and complete follow-up for vital status. Each becomes a written commitment in the protocol and the quality management plan: this is what the study says it will do.

Do: Do What You Say

Doing means turning commitments into routine behavior. Sites receive procedures for each critical factor, such as an echocardiogram reading by a core laboratory before randomization and a potassium check at fixed visits. Staff are trained on why each step matters, not only how to do it, because understanding the purpose reduces shortcuts under time pressure. Simple tools carry the commitments into practice: eligibility checklists in the electronic system, automated reminders for laboratory tests and a dosing diary for participants.

Check: Prove It

Checking provides evidence that the trial is doing what it said. Rather than verifying every data point, the sponsor uses central monitoring to watch indicators across sites: randomizations later found ineligible, missing potassium values, endpoint events awaiting adjudication and participants lost to follow-up. Quality tolerance limits, set during planning, define when a deviation becomes a signal. For example, if more than 3% of randomized participants turn out to be ineligible, the study team must investigate. On-site monitoring is then directed to the sites whose indicators suggest trouble.

Act: Improve It

Acting closes the loop. When central monitoring shows that one region has twice the missing potassium values of others, the team performs a root cause analysis and finds that a local laboratory schedule conflicts with clinic hours. The fix, a point-of-care test at the visit, is shared across all sites. When the data show that the endpoint definition is causing confusion about outpatient intravenous diuretic visits, the protocol is amended and sites retrained. Each improvement feeds the next planning cycle, and lessons are recorded for future trials.

Why the Cycle Works

The cycle works because it connects the four activities that are often separated in large organizations. Protocol writers plan, sites execute, monitors check and quality assurance investigates, but without a deliberate loop, what monitors find rarely changes what protocol writers do next time. The cycle also keeps effort proportional: by focusing on what is critical, it frees resources from checking data that do not affect safety or conclusions.

Conclusion

Building quality into a clinical trial means deciding in advance what matters, doing it consistently, proving it with targeted evidence and improving when the evidence shows a problem. Plan, Do, Check, Act gives that sequence a shape that regulators, sponsors and sites can share.

References

Meeker-O'Connell, A., Glessner, C., Behm, M., Mulinde, J., Roach, N., Sweeney, F., Tenaerts, P., & Landray, M. J. (2016). Enhancing clinical evidence by proactively building quality into clinical trials. Clinical Trials, 13(4), 439-444. https://doi.org/10.1177/1740774516643491

Pacifici, E., & Bain, S. (2018). An overview of FDA regulated products: From drugs and cosmetics to food and tobacco. Academic Press.

U.S. Food and Drug Administration. (2025). E6(R3) good clinical practice (GCP) [Guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp